BioNTech SE (FRA:22UA)
Germany · Delayed Price · Currency is EUR 80.00
+1.00 (1.27%)
At close: Dec 19, 2025
BioNTech SE Employees
BioNTech SE had 6,772 employees as of December 31, 2024. The number of employees increased by 639 or 10.42% compared to the previous year.
Employees
6,772
Change (1Y)
639
Growth (1Y)
10.42%
Revenue / Employee
€465,520
Profits / Employee
€84,406
Market Cap
18.98B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | 1,941 | 631 | 48.17% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 176,486 |
| Fresenius Medical Care AG | 111,513 |
| Bayer Aktiengesellschaft | 91,864 |
| Siemens Healthineers AG | 73,840 |
| Merck KGaA | 59,020 |
| Fielmann Group AG | 24,363 |
| Sartorius Aktiengesellschaft | 13,528 |
| Carl Zeiss Meditec AG | 5,784 |
BioNTech SE News
- 5 days ago - Noteworthy ETF Inflows: FNDF, APTV, BNTX, NXPI - Nasdaq
- 12 days ago - BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart - Seeking Alpha
- 12 days ago - BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options - Benzinga
- 12 days ago - BioNTech, Bristol-Myers Squibb Announce Interim Results From Pumitamig Study - Nasdaq
- 12 days ago - BioNTech SE: BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer - Finanz Nachrichten
- 12 days ago - BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer - GlobeNewsWire
- 14 days ago - BioNTech (BNTX) Sees Promising Survival Data in Lung Cancer Trial - GuruFocus
- 15 days ago - BioNTech SE: BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer - Finanz Nachrichten